Pcv2 immunogenic composition for lessening clinical symptoms in pigs

HK40041392BActive Publication Date: 2026-07-10BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
HK · HK
Patent Type
Patents
Current Assignee / Owner
BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC
Filing Date
2021-05-20
Publication Date
2026-07-10

AI Technical Summary

Technical Problem

Current vaccines for Porcine circovirus type 2 (PCV2) infections are ineffective in conferring protective immunity and do not address the clinical symptoms associated with the virus, such as lymphadenopathy, lymphoid depletion, and other related conditions in swine.

Method used

An immunogenic composition comprising recombinant PCV2 ORF2 protein is administered to young pigs to induce an immune response, reducing the severity of clinical symptoms like lymphadenopathy, lymphoid depletion, and other associated conditions.

Benefits of technology

The composition effectively lessens the severity of lymphadenopathy, lymphoid depletion, and other symptoms in swine, enhancing disease resistance and reducing the incidence of PCV2-associated diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000039_0000
    Figure 00000039_0000
  • Figure 00000040_0000
    Figure 00000040_0000
  • Figure 00000041_0000
    Figure 00000041_0000
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.